MedPath

Investigation of method for prediction of therapeutic effect of adalimumab initial therapy for inflammatory bowel disease

Not Applicable
Conditions
s disease
lcerative colitis, Crohn&#39
Registration Number
JPRN-UMIN000022727
Lead Sponsor
Ofuna Chuo Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

Patients who are considered not suitable for Adalimumab use due to contraindication or considerable risks such as hypersensitivity to Adalimumab. Other than above mentioned criteria, patients who are judged inappropriate by the doctor.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary end point was prediction of a clinical response at 6 months.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath